Caris Life Sciences, Inc. (CAI) · Nov 4, 2026 · Earnings
Beat — Revenue $275.4M vs ~$255–271M consensus; EPS $0.05 vs ~$0.02–0.03
Caris earnings beat published Q3 revenue and EPS estimates, while 2026 revenue guidance rose. The trade-off: heavier investment compressed margins and cash flow.
Caris is scaling an oncology precision-medicine platform beyond core molecular profiling into early detection, treatment monitoring and minimal-residual-disease testing. Its current business is still led by clinical case volume, while Caris Detect is newly commercial and Caris Confirm is still approaching launch.
The quarter cleared the operating bar. Total revenue reached $275.4 million, above the roughly $255–271 million range of available published estimates, while reported EPS of $0.05 exceeded estimates around $0.02–$0.03. Molecular profiling revenue grew 27% year over year, helped by higher case volume and average selling prices. The filing says, “The increase in total revenue was driven primarily by a 27% growth in molecular profiling services revenue.”
| Q3 2026 | Q3 2025 | Consensus / comparison | |
|---|---|---|---|
| Total revenue (Financial Data) | $275.4M (+27.0%) | $216.8M | ~$255–271M |
| Molecular profiling revenue (Financial Data) | $262.7M (+26.6%) | $207.6M | |
| Gross margin (Financial Data) | 66% (-2 pts) | 68% | |
| Diluted EPS (Financial Data) | $0.05 | $0.08 | ~$0.02–0.03 |
| Adjusted EBITDA (Adjusted EBITDA reconciliation) | $44.4M (-13.2%) | $51.2M | |
| Free cash flow (Free cash flow reconciliation) | $(39.7)M | $55.3M | |
| FY2026 revenue guidance (Outlook and Guidance) | $1.04–1.05B | $1.03–1.04B prior guide |
The raise is meaningful, but the growth engine is becoming more expensive. Caris lifted its full-year revenue range by $10 million at the midpoint and maintained its roughly 20% clinical therapy-selection volume-growth target. That is an upgrade from the prior quarter’s guidance, when management had set the range at $1.03–1.04 billion. At the same time, operating expenses rose 42%, gross margin fell to 66% from 68%, and adjusted EBITDA declined 13%. The filing attributes the spending increase to headcount, research and development and marketing investment.
Cash conversion is the main restraint on an otherwise better quarter. Operating cash flow swung to a $22.2 million use from $62.4 million of cash generation a year earlier, while free cash flow was negative $39.7 million. The filing points to commercial expansion, marketing, inventory build-up for new launches and research spending; supplies increased sharply during the first nine months, reinforcing that Caris is funding expansion ahead of possible returns.
Bottom line: Caris delivered a genuine earnings beat and raised revenue guidance, strengthening the core growth story. The positive signal is moderated by lower margins and a sharp cash-flow reversal as the company invests to commercialize its newer testing platforms.
Caris Confirm launch, targeted before year-end
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!